| Factor Information | |
|---|---|
| Data ID | 1744 |
| Factor | Infusions--Dopamine |
| Description | Although there was no sex mismatch, the dexmedetomidine group had a lower surgical complexity (risk adjustment for congenital heart surgery, version 1) category and less use of calcium chloride, dopamine, and epinephrine at PCICU admission. |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | examine for an association between dexmedetomidine use in the immediate postoperative period and subsequent arrhythmia development after heart surgery |
| p Value | <0.001 |
| Conclusion | Although there was no sex mismatch, the dexmedetomidine group had a lower surgical complexity (risk adjustment for congenital heart surgery, version 1) category and less use of calcium chloride, dopamine, and epinephrine at PCICU admission. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 25878324 |
| Year | 2015 |
| Title | Association between perioperative dexmedetomidine and arrhythmias after surgery for congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | an ongoing prospective observational study | |
| Region | Nashville, USA | |
| Method | prospective observational study | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | cardiac surgery | |
| Group | DEX(dexmedetomidine) group(Treatment) | CHD group without DEX(Control) |
| Number | 73 | 95 |
| Age | 784 (175 to 1794) days | 127 (13 to 379) days |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 16% (73) | 26% (295) |
